Advanced Cell Technology, Cytomedix and Mesoblast to Provide Corporate and Clinical Updates at Regen Med Investor Day
Alliance for Regenerative Medicine Announces Final Disease Session Panelists; 16 leading regenerative medicine companies discuss late stage and commercial products -
By Alliance for Regenerative Medicine
WASHINGTON, APRIL 9, 2013 — /PRNewswire/ -- At the first annual Regen Med Investor Day, Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), Cytomedix, Inc. (OTCQX: CMXI) and Mesoblast Limited will be just three of the 16 leading regenerative medicine companies providing updates on recent corporate and clinical milestones. The Alliance for Regenerative Medicine also announced today that the final panelists have been determined for the three disease sessions which will focus on cardiovascular disease, wound healing and tissue engineering and CNS diseases. The Regen Med Investor Day is the first investor event organized specifically for the regenerative medicine sector and will take place next Wednesday, April 17 at the Harmonie Club, 4 East 60th Street, New York, NY.
Presentation Highlights In addition to the three companies featured below, the program will include presentations by: Aastrom, Asterias, Athersys, Cytori, Juventas, MiMedx, NeoStem, Organogenesis, Organovo, Pluristem, Sangamo, StemCells, Inc. and Tigenix.
About the Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field.
It's still early but hopefully a cumulative effect of all the info will spark some interest. I'm trying not to come on here too often because it can be self-defeating insofar as positive attitude about this stock. I can't resist coming on and letting the GOP CON clowns who destroyed our economy once in a while. They get a little "grand" sometimes and forget that they are big time losers. LOL.
Lord, you are quite the downer. You beg every day for news and then when you get it, its never enough. You simply don't have the temperment for watching a stock day in and out. To get to a commerical product will take MANY incremental steps, many of which by themselves will appear boring, but in the aggregate will be what we've been waiting for.